Agilent to Sponsor Global Forensics Congress in Portugal
News Aug 27, 2013
Agilent Technologies Inc. has announced that it will host a series of scientific presentations at the annual meeting of the International Association of Forensic Toxicologists (TIAFT), Sept. 2-6, in Madeira, Portugal.
TIAFT is a prominent international forensics trade association. Its annual congress draws hundreds of forensic and analytical toxicologists from all over the world.
“For over a decade, Agilent has been a proud sponsor of TIAFT’s international meetings and the association’s mission to promote education, training and research in forensic toxicology and related disciplines,” said Tom Gluodenis, Agilent’s global marketing manager of Forensics and Toxicology. “We are pleased to continue our support for this forum highlighting the latest advances in measurement technology.”
Agilent Program Highlights
Tuesday evening keynote address: “Analytical Identification - At the Core of the EU Early Warning System,” presented by Dr. Andrew Cunningham of the European Monitoring Centre for Drugs & Drug Addiction, Lisbon.
Wednesday technical presentation: “Latest Advances in GC/MS, LC/MS, Spectroscopy and Sample-Preparation Technologies for Isometric/Designer Drugs, Drug Metabolite Analysis and Trace Metal Analysis,” presented by Agilent scientists Bernhard Wüest, Juan Aybar, Jaume Morales, Dr. Amparo Villar and Laure Blanc.
Poster presentation: “Ethylglucuronide Determination in Hair as an Indicator of Chronic Alcohol Abuse - A Fully Validated Method in GC-EI-MS/MS,” presented by Dr. Jennifer Pascali, DTOLabs (Agilent authorized partner laboratory), Resana, Italy, and Dr. Franco Tagliaro, Department of Public Health and Community Medicine, Section of Forensic Medicine, University of Verona, Verona, Italy.
Attendees are also invited to visit Agilent’s exhibit (Booth No. 1) to talk with scientists and view the company’s latest advances in sample-preparation technology, chromatography, spectrometry and mobile-measurement solutions for use in forensic toxicology, anti-doping initiatives and related applications.
Cell Recycling System Offers Therapeutic Entry Point for Rare Disease TreatmentNews
Scientists have demonstrated how an investigational drug works against a rare, fatal genetic disease, Niemann-Pick type C1 (NPC1).READ MORE
Cancer Cells Force Normal Cells to Act Like Viruses, Helping Tumors SpreadNews
Researchers reveal how cancer cells force normal cells to act like viruses – allowing tumors to grow, resist treatment, and spread.READ MORE
Edith Heard Unanimously Selected as Next Director General of EMBLNews
At its 53rd meeting yesterday, EMBL Council selected Edith Heard as the organization’s fifth Director General. Heard’s mandate is scheduled to begin 1 January 2019.READ MORE
Comments | 0 ADD COMMENT
EMBL Conference: European Conference of Life Science Funders and Foundations
Apr 19 - Apr 20, 2018
EMBL Course: Target Engagement in Biology and Drug Discovery
Feb 19 - Feb 23, 2018